Publicaciones en colaboración con investigadores/as de Hospital Regional Universitario de Málaga (13)

2021

  1. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation

    Annals of Hematology, Vol. 100, Núm. 2, pp. 541-553

2019

  1. Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation

    Blood Advances, Vol. 3, Núm. 21, pp. 3351-3359

2018

  1. A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms

    Blood Advances, Vol. 2, Núm. 14, pp. 1719-1737

  2. Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes

    European Journal of Haematology, Vol. 101, Núm. 3, pp. 332-339

  3. PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation

    Annals of Hematology, Vol. 97, Núm. 11, pp. 2217-2224

2017

  1. Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 12, pp. 2042-2047

  2. Single umbilical cord blood with or without CD341 cells from a third-party donor in adults with leukemia

    Blood Advances, Vol. 1, Núm. 15, pp. 1047-1055

2016

  1. Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience

    Bone Marrow Transplantation, Vol. 51, Núm. 10, pp. 1307-1312

  2. UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation

    Bone Marrow Transplantation, Vol. 51, Núm. 1, pp. 79-82

2015

  1. Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT

    Bone Marrow Transplantation

  2. The genotype of the donor for the (GT)n polymorphism in the promoter/enhancer of FOXP3 Is associated with the development of severe acute GVHD but does not affect the GVL effect after myeloablative HLA-Identical allogeneic stem cell transplantation

    PLoS ONE, Vol. 10, Núm. 10

2013

  1. A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT

    Bone Marrow Transplantation, Vol. 48, Núm. 9, pp. 1205-1211

2005

  1. Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms

    Leukemia, Vol. 19, Núm. 3, pp. 336-343